Study: A 52-week randomized, double-blind, placebocontrolled,
multi-center Phase 2b study with a 52-week blinded extension
assessing safety and efficacy of frexalimab, a
CD40Lantagonist
monoclonal antibody, for preservation of
pancreatic β-cell function in adults and adolescents with newly
diagnosed type 1 diabetes on insulin therapy
Please Select Your Affiliation with CU Anschutz
Thank you for expressing your interest in a research study and for taking the time to provide your information.
By clicking 'Submit', your information will be shared with the research team. Typically a member of the research team will contact you within 3 to 5 business days.
Please understand that:
- The research team will need to determine whether you are eligible for the study. Clicking 'Submit' does not enroll you into the study, or guarantee that you qualify for the study.
- It is always your choice to participate.
Thanks again. Volunteers such as yourself are at the core of our work.
